ProCE Banner Activity

Rigosertib + Azacitidine in Patients With Higher-Risk MDS

Slideset Download
Conference Coverage
Data from this small study suggest rigosertib plus azacitidine therapy may be effective and safe in this setting.

Released: December 14, 2015

Expiration: December 12, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen